Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

(2015) M. Weller et al.   CLINICAL CANCER RESEARCH

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

(2015) Florian Ringel et al.   NEURO-ONCOLOGY

Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM

(2015) B. Suchorska et al.   NEUROLOGY

An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity

(2014) Mark E. Oppenlander et al.   JOURNAL OF NEUROSURGERY

Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma

(2014) Matthew M. Grabowski et al.   JOURNAL OF NEUROSURGERY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

(2014) Michael Weller et al.   LANCET ONCOLOGY

Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010

(2014) F. Nava et al.   NEURO-ONCOLOGY

Reoperation for Recurrent High-Grade Glioma

(2014) Shawn L. Hervey-Jumper et al.   NEUROSURGERY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy†

(2013) F. -W. Kreth et al.   ANNALS OF ONCOLOGY

Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma

(2013) Kaisorn L. Chaichana et al.   NEURO-ONCOLOGY

A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma

(2013) C.-K. Park et al.   NEURO-ONCOLOGY

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials

(2012) Thierry Gorlia et al.   EUROPEAN JOURNAL OF CANCER

Impact of extent of resection for recurrent glioblastoma on overall survival

(2012) Orin Bloch et al.   JOURNAL OF NEUROSURGERY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

An extent of resection threshold for newly diagnosed glioblastomas

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

(2011) J. L. Clarke  et al.   NEURO-ONCOLOGY

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

(2010) Martin J.B. Taphoorn et al.   EUROPEAN JOURNAL OF CANCER

Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme

(2010) John K. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic options for recurrent malignant glioma

(2010) Maximilian Niyazi et al.   RADIOTHERAPY AND ONCOLOGY

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

(2009) et al.   NEUROSURGERY